Literature DB >> 14506696

Clustering of hypermethylated genes in neuroblastoma.

Max M van Noesel1, Saskia van Bezouw, P A Voûte, James G Herman, Rob Pieters, Rogier Versteeg.   

Abstract

CpG-island hypermethylation of gene promoters is a frequent mechanism for gene inactivation in tumors. Many neuroblastomas have hypermethylation and down-regulation of CASP8, leading to resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). We recently found hypermethylation of the four TRAIL receptors in 9 neuroblastoma cell lines. Here, we analyzed methylation of 34 genes in 22 neuroblastoma cell lines. Of the 29 newly analyzed genes, only FLIP at chromosome band 2q33 was methylated in 8/22 cell lines. The FLIP protein is a negative regulator of Caspase 8. FLIP maps adjacent to CASP8, and their methylation patterns showed a moderate correlation. Furthermore, co-methylation patterns were observed for the TRAIL receptor pairs DCR1 and DCR2 and between DR4 and DR5. All four receptors co-localize in chromosome band 8p21. The 6 genes methylated in neuroblastomas appeared to occur in pairs. The genes within each pair have a strong sequence homology and originated from gene duplication. We found no evidence for regional spreading of methylation, given that we did not observe de novo methylation in additional local CpG islands. However, the gene pairs showed a striking co-regulation at the mRNA expression level. Down-regulation of FLIP strongly corresponds with down-regulation of CASP8, and this was also found for DCR1 and DCR2. Only a subset of the down-regulated genes was methylated. This suggests a mechanism of co-regulated transcriptional silencing of the gene pairs, followed by a methylation event that is less penetrating. The methylation pattern therefore supports a model in which CpG islands are not randomly targeted by methylation in cancer. Specific transcriptional silencing probably marks genes that can become methylated. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506696     DOI: 10.1002/gcc.10278

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

1.  Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.

Authors:  Rani E George; Jill M Lahti; Peter C Adamson; Kejin Zhu; David Finkelstein; A Mark Ingle; Joel M Reid; Mark Krailo; Donna Neuberg; Susan M Blaney; Lisa Diller
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

2.  Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity.

Authors:  Marcel W Coolen; Clare Stirzaker; Jenny Z Song; Aaron L Statham; Zena Kassir; Carlos S Moreno; Andrew N Young; Vijay Varma; Terence P Speed; Mark Cowley; Paul Lacaze; Warren Kaplan; Mark D Robinson; Susan J Clark
Journal:  Nat Cell Biol       Date:  2010-02-21       Impact factor: 28.824

Review 3.  Neonatal tumours.

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2013-10-31       Impact factor: 1.827

4.  RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis.

Authors:  Farhan Basit; Robin Humphreys; Simone Fulda
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

Review 5.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

6.  Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping.

Authors:  Pei-Yin Hsu; Hang-Kai Hsu; Gregory A C Singer; Pearlly S Yan; Benjamin A T Rodriguez; Joseph C Liu; Yu-I Weng; Daniel E Deatherage; Zhong Chen; Julia S Pereira; Ricardo Lopez; Jose Russo; Qianben Wang; Coral A Lamartiniere; Kenneth P Nephew; Tim H-M Huang
Journal:  Genome Res       Date:  2010-05-04       Impact factor: 9.043

7.  Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.

Authors:  Dolly G Aguilera; Chandra M Das; Neeta D Sinnappah-Kang; Celine Joyce; Pete H Taylor; Sijin Wen; Martin Hasselblatt; Werner Paulus; Greg Fuller; Johannes E Wolff; Vidya Gopalakrishnan
Journal:  J Neurooncol       Date:  2009-01-16       Impact factor: 4.130

8.  Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines.

Authors:  Floor A M Duijkers; Renee X de Menezes; Inès J Goossens-Beumer; Dominique J P M Stumpel; Pieter Admiraal; Rob Pieters; Jules P P Meijerink; Max M van Noesel
Journal:  Cell Oncol (Dordr)       Date:  2013-07-18       Impact factor: 6.730

Review 9.  Targeting cell death in tumors by activating caspases.

Authors:  Sarah H MacKenzie; A Clay Clark
Journal:  Curr Cancer Drug Targets       Date:  2008-03       Impact factor: 3.428

10.  Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.

Authors:  Chun-Yen Tsao; Francesco Sabbatino; Nai-Kong V Cheung; Jeff Chi-Feng Hsu; Vincenzo Villani; Xinhui Wang; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.